secwatch.observer — SEC 8-K summary
======================================

Issuer:     Curanex Pharmaceuticals Inc (CURX)
CIK:        0002025942
Form:       8-K
Filed at:   2026-03-06T23:59:59+00:00
Accession:  0001493152-26-009155
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Curanex Pharmaceuticals formalizes CEO/COO agreements; base salaries $393,600 and $180,000
--------------------------------------------------------------------------------

- CEO Jun Liu: annual base salary $393,600, three-year term, plus $3,998/month auto lease.
- COO Dr. Liqin Xie: annual salary $180,000, at-will employment, three-month severance on without-cause termination.
- CEO served without compensation from Feb 2024 to Aug 2025; received $325,000.08 for past services through March 1, 2026.
- Both agreements include 18-month non-compete (CEO), non-solicitation, and clawback provisions under policy effective Aug 12, 2025.
- Termination without cause or for good reason triggers 3 months' salary continuation and immediate equity vesting for both.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2025942/000149315226009155/0001493152-26-009155-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2025942/000149315226009155/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-009155

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer